Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates

Journal of Controlled Release

Volumn 167, Issue 2, 2013, Pages 200-209

  Senanayake, Thulani H ^a   Warren, Galya ^a   Wei, Xin ^a   Vinogradov, Serguei V ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Drug resistant animal tumor xenografts; Gemcitabine; Nanogel drug conjugates; Oral drug administration; Phosphorylated nucleoside analogs

Indexed keywords

DRUG ADMINISTRATION; GEMCITABINE; NANOGEL-DRUG CONJUGATES; NUCLEOSIDE ANALOGS; TUMOR XENOGRAFTS;

ANIMALS; BIOMOLECULES; CELLS; CHEMOTHERAPY; DISEASES; PHOSPHORYLATION; POLYMERS; TUMORS;

NANOSTRUCTURED MATERIALS;

CYTARABINE; FLOXURIDINE; GEMCITABINE; GEMCITABINE TRIPHOSPHATE; NANOCONJUGATE; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG EFFICACY; DRUG RELEASE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HYDROLYSIS; IN VITRO STUDY; LIFESPAN; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PERMEABILITY; PRIORITY JOURNAL; STOMACH PH; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ALKALINE PHOSPHATASE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CHOLESTEROL; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYDROLYSIS; MICE; MICE, NUDE; NANOSTRUCTURES; NEOPLASMS; PARTICLE SIZE; PERMEABILITY; PHOSPHORIC DIESTER HYDROLASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874397185     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.01.020     Document Type: Article

References (36)

1. T.H. Senanayake, G. Warren, and S.V. Vinogradov Novel anticancer polymeric conjugates of activated nucleoside analogues Bioconjug. Chem. 22 2011 1983 1993
2. J.P. Hale, and I.J. Lewis Anthracyclines: cardiotoxicity and its prevention Arch. Dis. Child. 71 1994 457 462
3. L.W. Jones, M.J. Haykowsky, J.J. Swartz, P.S. Douglas, and J.R. Mackey Early breast cancer therapy and cardiovascular injury J. Am. Coll. Cardiol. 50 2007 1435 1441
4. D.D. Von Hoff, M.W. Layard, P. Basa, H.L. Davis Jr., A.L. Von Hoff, M. Rozencweig, and F.M. Muggia Risk factors for doxorubicin-induced congestive heart failure Ann. Intern. Med. 91 1979 710 717
5. S.E. Lipshultz, S.D. Colan, R.D. Gelber, A.R. Perez-Atayde, S.E. Sallan, and S.P. Sanders Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood N. Engl. J. Med. 324 1991 808 815
6. A. Moreno-Aspitia, and E.A. Perez Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends Clin. Ther. 31 2009 1619 1640
7. P. Schmid, J. Krocker, C. Jehn, K. Michniewicz, S. Lehenbauer-Dehm, H. Eggemann, V. Heilmann, S. Kummel, C.O. Schulz, A. Dieing, M.B. Wischnewsky, S. Hauptmann, D. Elling, K. Possinger, and B. Flath Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial Ann. Oncol. 16 2005 1624 1631
8. C.M. Galmarini, J.R. Mackey, and C. Dumontet Nucleoside analogues and nucleobases in cancer treatment Lancet Oncol. 3 2002 415 424
9. W.P. Gati, A.R. Paterson, A.R. Belch, V. Chlumecky, L.M. Larratt, M.J. Mant, and A.R. Turner Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC) Leuk. Lymphoma 32 1998 45 54
10. J. Spratlin, R. Sangha, D. Glubrecht, L. Dabbagh, J.D. Young, C. Dumontet, C. Cass, R. Lai, and J.R. Mackey The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma Clin. Cancer Res. 10 2004 6956 6961
11. T. Kakihara, T. Fukuda, A. Tanaka, I. Emura, K. Kishi, K. Asami, and M. Uchiyama Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: decreased expression of dCK gene in relapsed leukemia Leuk. Lymphoma 31 1998 405 409
12. J. Zhang, F. Visser, K.M. King, S.A. Baldwin, J.D. Young, and C.E. Cass The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs Cancer Metastasis Rev. 26 2007 85 110
13. C.M. Galmarini, N. Voorzanger, N. Falette, L. Jordheim, E. Cros, A. Puisieux, and C. Dumontet Influence of p53 and p21(WAF1) expression on sensitivity of cancer cells to cladribine Biochem. Pharmacol. 65 2003 121 129
14. S.V. Vinogradov, A.D. Zeman, E.V. Batrakova, and A.V. Kabanov Polyplex nanogel formulations for drug delivery of cytotoxic nucleoside analogs J. Control. Release 107 2005 143 157
15. J.W. Lee, J.H. Park, and J.R. Robinson Bioadhesive-based dosage forms: the next generation J. Pharm. Sci. 89 2000 850 866
16. J. Kreuter Evaluation of nanoparticles as drug-delivery systems. II: comparison of the body distribution of nanoparticles with the body distribution of microspheres (diameter greater than 1 micron), liposomes, and emulsions Pharm. Acta Helv. 58 1983 217 226
17. J. Kreuter Liposomes and nanoparticles as vehicles for antibiotics Infection 19 Suppl. 4 1991 S224 S228
18. G.V. Koukourakis, G. Zacharias, J. Tsalafoutas, D. Theodoridis, and V. Kouloulias Capecitabine for locally advanced and metastatic colorectal cancer: a review World J. Gastrointest. Oncol. 2 2010 311 321
19. S.A. Veltkamp, R.S. Jansen, S. Callies, D. Pluim, C.M. Visseren-Grul, H. Rosing, S. Kloeker-Rhoades, V.A. Andre, J.H. Beijnen, C.A. Slapak, and J.H. Schellens Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study Clin. Cancer Res. 14 2008 3477 3486
20. L. Mu, and S.S. Feng Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol) J. Control. Release 80 2002 129 144
21. K.Y. Win, and S.S. Feng Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs Biomaterials 26 2005 2713 2722
22. T. Yamaoka, Y. Tabata, and Y. Ikada Comparison of body distribution of poly(vinyl alcohol) with other water-soluble polymers after intravenous administration J. Pharm. Pharmacol. 47 1995 479 486
23. A.T. Bender, and J.A. Beavo Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use Pharmacol. Rev. 58 2006 488 520
24. B. Uznanski, A. Grajkowski, and A. Wilk The isopropoxyacetic group for convenient base protection during solid-support synthesis of oligodeoxyribonucleotides and their triester analogs Nucleic Acids Res. 17 1989 4863 4871
25. B. Ghosn, A.L. van de Ven, J. Tam, A. Gillenwater, K.V. Sokolov, R. Richards-Kortum, and K. Roy Efficient mucosal delivery of optical contrast agents using imidazole-modified chitosan J. Biomed. Opt. 15 2010 015003
26. H. Maeda Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects Bioconjug. Chem. 21 2010 797 802
27. W. Jiang, B.Y. Kim, J.T. Rutka, and W.C. Chan Nanoparticle-mediated cellular response is size-dependent Nat. Nanotechnol. 3 2008 145 150
28. B.D. Chithrani, A.A. Ghazani, and W.C. Chan Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells Nano Lett. 6 2006 662 668
29. D. Das, and S. Lin Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration J. Pharm. Sci. 94 2005 1343 1353
30. M. Garcia-Diaz, M. Avalos, and J.C. Cameselle Methanol esterification reactions catalyzed by snake venom and bovine intestinal 5′-nucleotide phosphodiesterases. Formation of nucleoside 5′-monophosphate methyl esters from guanosine 5′-triphosphate and other nucleoside 5′- polyphosphates Eur. J. Biochem. 196 1991 451 457
31. P. Artursson Epithelial transport of drugs in cell culture. I: a model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells J. Pharm. Sci. 79 1990 476 482
32. S. Chong, S.A. Dando, and R.A. Morrison Evaluation of biocoat intestinal epithelium differentiation environment (3-day cultured Caco-2 cells) as an absorption screening model with improved productivity Pharm. Res. 14 1997 1835 1837
33. I.J. Hidalgo, T.J. Raub, and R.T. Borchardt Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability Gastroenterology 96 1989 736 749
34. C.P. Landowski, X. Song, P.L. Lorenzi, J.M. Hilfinger, and G.L. Amidon Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism Pharm. Res. 22 2005 1510 1518
35. M. Hayashi, and M. Tomita Mechanistical analysis for drug permeability through intestinal membrane Drug Metab. Pharmacokinet. 22 2007 67 77
36. C.M. Galmarini, G. Warren, M.T. Senanayake, and S.V. Vinogradov Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs Int. J. Pharm. 395 2010 281 289